Dear editor
We are writing this letter in response to the article "Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era" by Berger et 2 Lipo-Dox is manufactured by TTY Biopharm, and has a lipid formulation different to that of Doxil and has a longer half-life; 3 it has been sold in Taiwan and many Asian countries since 1998, and is probably the alternative formulation referenced in the paper by Berger et al. 1 Berger et al incorrectly referenced two Asian ovarian cancer trials for efficacy and survival data for Lipodox, and we need to set the record straight that the Taiwanese trial used TTY Biopharm Lipo-Dox, 4 and that the Japanese trial most likely used the originator Doxil. 5 Another smaller study using single-agent TTY Biopharm Lipo-Dox in patients with ovarian cancer refractory to both cisplatin and paclitaxel produced efficacy similar to that reported by Chou et al 6 but with no serious toxicity because of a slightly lower dose (see Table 1 ).
Disclosure
The authors report no conflicts of interest in this communication. 
